Speech and language biomarkers for Parkinson’s disease prediction, early diagnosis and progression.

Publication date: Mar 24, 2025

Parkinson’s disease (PD), a multifaceted neurodegenerative disorder, can manifest as an array of motor and non-motor symptoms. Among these, speech and language impairments are particularly prevalent, often preceding motor dysfunctions. Emerging research indicates that these impairments may serve as early disease indicators. In this narrative review, we synthesised current findings on the potential of speech and language symptoms in PD identification and progression monitoring. Our review highlights convergent, albeit preliminary, lines of evidence supporting the value of speech-related features in detecting early or prodromal PD, even across language groups, especially with sophisticated analytical techniques. Distinct speech patterns in PD subtypes and other neurological disorders may assist in differential diagnosis and inform targeted management efforts. These features also evolve over the disease course and could effectively be utilised for disease tracking and guide management plan modifications. Advances in digital voice processing allow cost-effective, remote and scalable monitoring for larger populations.

Open Access PDF

Concepts Keywords
Biomarkers Biomarkers
Neurodegenerative Diagnosis
Parkinson Early
Remote Impairments
Speech Management
Monitoring
Motor
Multifaceted
Neurodegenerative
Parkinson
Pd
Prediction
Progression
Speech
Symptoms

Semantics

Type Source Name
disease MESH Parkinson’s disease
disease MESH neurodegenerative disorder
disease MESH neurological disorders
disease MESH resting tremor
disease MESH pathogenesis
drug DRUGBANK Dopamine
disease MESH parasomnia
disease MESH dementia
disease MESH atrophy
pathway KEGG Parkinson disease
disease MESH dysarthria
drug DRUGBANK MK-212
disease MESH facial expression
disease MESH abnormalities
disease MESH hyposmia
disease MESH synucleinopathy
disease MESH gait
drug DRUGBANK Coenzyme M
disease MESH mild cognitive impairment
drug DRUGBANK Trestolone
disease MESH syndromes
disease MESH progressive supranuclear palsy
disease MESH Parkinsonism
disease MESH spastic
disease MESH stuttering
disease MESH ataxia
disease MESH apathy
disease MESH depression
disease MESH movement disorders
disease MESH dysphonia
disease MESH essential tremor
drug DRUGBANK Isoxaflutole
drug DRUGBANK Levodopa
drug DRUGBANK L-Leucine
disease MESH posture
disease MESH pathological processes
disease MESH lifestyle
drug DRUGBANK Tropicamide
disease MESH Clinical progression
disease MESH REM sleep behavior disorder
disease MESH sleep disorders
disease MESH Huntington’s disease
disease MESH multiple system atrophy
disease MESH sclerosis
disease MESH multiple sclerosis
drug DRUGBANK Fenamole
disease MESH Impaired Olfaction
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH speech disorders
drug DRUGBANK Flunarizine
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *